Related Experiment Video
Updated: Jun 22, 2026
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Role of the serotonergic system in reduced pulmonary function after exposure to methamphetamine
Sandra M Wells1, Mary C Buford, Virginia M Porter
1Department of Environmental, Agricultural and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska 68198-5910, USA. smwells@unmc.edu
Abstract:
Although use of methamphetamine (MA) by smoking is the fastest growing method of administration, very limited data are available describing the effects of smoked MA. Using a murine inhalation exposure system, we explored the pulmonary effects of low-dose acute inhalation exposure to MA vapor (smoke). Inhalation of MA vapor resulted in transiently reduced pulmonary function, as measured by transpulmonary resistance, dynamic compliance, and whole-body plethysmography compared with unexposed control animals. These changes were associated with an approximately 34% reduction in serotonin (5-hydroxytryptamine [5-HT]) metabolism/inactivation to 5-hydroxyindolacetic acid, and a nearly 40% reduction in monoamine oxidase (MAO)-A activity in the lung. Pretreatment of mice with a selective 5-HT reuptake inhibitor completely ablated the MA-induced changes in pulmonary function, confirming a key role for the 5-HT transporter (serotonin transporter [SERT]) and the serotonergic system in this effect. Immunofluorescent staining of mouse lung tissue confirmed high expression of SERT in airway epithelial cells. Using mouse airway epithelial cell line, LA-4, and purified human MAO-A, it was demonstrated that MA impedes 5-HT metabolism through direct inhibition of MAO-A activity in vitro. Together, these data demonstrate that low-dose exposure to MA results in reduced pulmonary function mediated via SERT and subsequent perturbation of 5-HT metabolism in the lung. This supports a role for the serotonergic system in MA-mediated pulmonary effects.
Insights
Smoking methamphetamine (MA) impairs lung function by affecting serotonin (5-HT) metabolism. This study reveals MA
Area of Science:
- Pulmonary toxicology
- Neuropharmacology
- Serotonergic system research
Background:
- Smoking is the fastest-growing methamphetamine (MA) administration route, yet its pulmonary effects are poorly understood.
- Limited data exist on the pulmonary consequences of inhaled MA exposure.
Purpose of the Study:
- To investigate the pulmonary effects of low-dose acute inhalation exposure to MA vapor in a murine model.
- To elucidate the role of the serotonergic system, specifically serotonin transporter (SERT) and monoamine oxidase A (MAO-A), in MA-induced pulmonary dysfunction.
Main Methods:
- Utilized a murine inhalation exposure system to administer MA vapor.
- Assessed pulmonary function using transpulmonary resistance, dynamic compliance, and whole-body plethysmography.
- Measured serotonin metabolism and MAO-A activity in lung tissue; employed immunofluorescent staining and in vitro assays with cell lines (LA-4) and purified MAO-A.
Main Results:
- Inhaled MA vapor caused transiently reduced pulmonary function in mice.
- Observed significant reductions in lung serotonin metabolism and MAO-A activity.
- MA-induced pulmonary changes were abolished by selective serotonin reuptake inhibitor pretreatment, implicating SERT and the serotonergic system.
Conclusions:
- Low-dose MA inhalation impairs pulmonary function through SERT-mediated mechanisms and disruption of serotonin metabolism in the lung.
- MA directly inhibits MAO-A activity in airway epithelial cells, contributing to altered 5-HT metabolism.
- These findings highlight the serotonergic system's critical role in MA-induced pulmonary effects.
Related Concept Videos
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:23Antidepressant Drugs: MAOIs and Other Agents
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:29Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...